Silica vesicle nanovaccine formulations stimulate long-term immune responses to the bovine viral diarrhoea virus e2 protein

Mody, Karishma T., Mahony, Donna, Cavallaro, Antonino S., Zhang, Jun, Zhang, Bing, Mahony, Timothy J., Yu, Chengzhong and Mitter, Neena (2015) Silica vesicle nanovaccine formulations stimulate long-term immune responses to the bovine viral diarrhoea virus e2 protein. PLoS One, 10 12: 1-16. doi:10.1371/journal.pone.0143507


Author Mody, Karishma T.
Mahony, Donna
Cavallaro, Antonino S.
Zhang, Jun
Zhang, Bing
Mahony, Timothy J.
Yu, Chengzhong
Mitter, Neena
Title Silica vesicle nanovaccine formulations stimulate long-term immune responses to the bovine viral diarrhoea virus e2 protein
Formatted title
Silica vesicle nanovaccine formulations stimulate long-term immune responses to the bovine viral diarrhoea virus e2 protein
Journal name PLoS One   Check publisher's open access policy
ISSN 1932-6203
Publication date 2015-12-01
Year available 2015
Sub-type Article (original research)
DOI 10.1371/journal.pone.0143507
Open Access Status DOI
Volume 10
Issue 12
Start page 1
End page 16
Total pages 16
Place of publication San Francisco, CA United States
Publisher Public Library of Science
Collection year 2016
Language eng
Formatted abstract
Bovine Viral Diarrhoea Virus (BVDV) is one of the most serious pathogen, which causes tremendous economic loss to the cattle industry worldwide, meriting the development of improved subunit vaccines. Structural glycoprotein E2 is reported to be a major immunogenic determinant of BVDV virion. We have developed a novel hollow silica vesicles (SV) based platform to administer BVDV-1 Escherichia coli-expressed optimised E2 (oE2) antigen as a nanovaccine formulation. The SV-140 vesicles (diameter 50 nm, wall thickness 6 nm, perforated by pores of entrance size 16 nm and total pore volume of 0.934 cm3g-1) have proven to be ideal candidates to load oE2 antigen and generate immune response. The current study for the first time demonstrates the ability of freeze-dried (FD) as well as non-FD oE2/SV140 nanovaccine formulation to induce long-term balanced antibody and cell mediated memory responses for at least 6 months with a shortened dosing regimen of two doses in small animal model. The in vivo ability of oE2 (100 μg)/SV-140 (500 μg) and FD oE2 (100 μg)/SV-140 (500 μg) to induce long-term immunity was compared to immunisation with oE2 (100 μg) together with the conventional adjuvant Quil-A from the Quillaja saponira (10 μg) in mice. The oE2/SV-140 as well as the FD oE2/SV-140 nanovaccine generated oE2-specific antibody and cell mediated responses for up to six months post the final second immunisation. Significantly, the cell-mediated responses were consistently high in mice immunised with oE2/SV-140 (1,500 SFU/million cells) at the six-month time point. Histopathology studies showed no morphological changes at the site of injection or in the different organs harvested from the mice immunised with 500 μg SV-140 nanovaccine compared to the unimmunised control. The platform has the potential for developing single dose vaccines without the requirement of cold chain storage for veterinary and human applications.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 03 Jan 2016, 10:20:11 EST by System User on behalf of Qld Alliance for Agriculture and Food Innovation